NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease<
02 Feb 2022

NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

SEFA-6179 is NST’s third programme to enter the clinic.
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer<
01 Feb 2022

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic
Lava Therapeutics annouces participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022<
28 Jan 2022

Lava Therapeutics annouces participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

Access to the recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics website.
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care<
27 Jan 2022

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury<
26 Jan 2022

AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury

The article provides insights on important advances in the understanding of AKI as a disease spectrum with an urgent need for new treatments.
LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference<
18 Jan 2022

LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference

New non-human primate data support the safety and tolerability profile of LAVA’s lead solid tumor GammabodyTM programs

Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer<
05 Jan 2022

Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

Dr. Oestreich brings extensive experience in business and drug development
Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022<
20 Dec 2021

Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022

Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022.
Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference<
20 Dec 2021

Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference

Stephen Hurlywill present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders<
17 Dec 2021

NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders

The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка